LIVE POLIO IRUS VACCINES

Development and Persistence of Polio Antibodies in Young Adults 239
eases. The analysis of all potential non-specific
factors should be the first step in this investigation.
REFERENCES
1. Ward, R., Chang, C., and Rader, D.: Importance
of optimum amounts of virus to demonstrate
neutralizing antibody rise in convalescent
poliomyelitis sera. Proc. Soc. Exp. Biol.
90: 162-165, 1955.
2. Brunner, K. T., and Ward, R.: Differences in
stability of antigen-antibody complexes formed
with poliovirus and acute and convalescent
phase human sera. J. Immun. 83: 405-410,
1959.
3. Sabin, A. B.: Properties of attenuated polioviruses
and their behavior in human beings.
New York Academy of Sciences, Monograph
no. 5: 113-127, 1957.
4. Vonka, V., Zácek, K., and Duben, J.: Paper
presented at the International Symposium on
Live Poliovirus Vaccine, Moscow, May 1960.
5. Gard, S.: Neutralization of Theiler's virus.
Acta Path. Microb. Scand. 37: 21-30, 1955.
6. -- Immuno-inactivation of poliovirus.
Arch. ges. Virusforsch. 7: 449-460, 1957.
7. Skovránek, V., Zácek, K., Vonka, V., Adam,
E., Adamová, V., Burian V., and Vojtová, H.:
Field trial with Sabin's live poliovirus vaccine
in Czechoslovakia-1958-1959. In: Live Poliovirus
Vaccines, First International Conference.
Scient. Pub. no. 44 of the Pan American
Health Organization, pp. 530-571, 1959.
8. Gelfand, H. M., LeBlanc, D., Fox, J. P., and
Potash, L.: Studies on the development of
natural immunity to poliomyelitis in Louisiana.
III. The serological response to commercially
produced "Salk vaccine" of children
totally or partially susceptible to poliovirus infection.
Am. J. Hyg. 70: 303-311, 1959.
9. Black, F. L., and Melnick, J. L.: Appearance
of soluble and cross-reactive complement-fixing
antigens on treatment of poliovirus with
formalin. Proc. Soc. Exp. Biol. 89: 353-355,
1955.